Cite
Increased reporting of cerebrovascular accidents with use of risankizumab observed in the Food and Drug Administration Adverse Events Reporting System (FAERS).
MLA
Egeberg, Alexander, and Jacob P. Thyssen. “Increased Reporting of Cerebrovascular Accidents with Use of Risankizumab Observed in the Food and Drug Administration Adverse Events Reporting System (FAERS).” British Journal of Dermatology, vol. 188, no. 6, June 2023, pp. 793–94. EBSCOhost, https://doi.org/10.1093/bjd/ljad039.
APA
Egeberg, A., & Thyssen, J. P. (2023). Increased reporting of cerebrovascular accidents with use of risankizumab observed in the Food and Drug Administration Adverse Events Reporting System (FAERS). British Journal of Dermatology, 188(6), 793–794. https://doi.org/10.1093/bjd/ljad039
Chicago
Egeberg, Alexander, and Jacob P Thyssen. 2023. “Increased Reporting of Cerebrovascular Accidents with Use of Risankizumab Observed in the Food and Drug Administration Adverse Events Reporting System (FAERS).” British Journal of Dermatology 188 (6): 793–94. doi:10.1093/bjd/ljad039.